PL3268356T3 - Związki heterocykliczne i sposoby ich stosowania - Google Patents

Związki heterocykliczne i sposoby ich stosowania

Info

Publication number
PL3268356T3
PL3268356T3 PL16715616T PL16715616T PL3268356T3 PL 3268356 T3 PL3268356 T3 PL 3268356T3 PL 16715616 T PL16715616 T PL 16715616T PL 16715616 T PL16715616 T PL 16715616T PL 3268356 T3 PL3268356 T3 PL 3268356T3
Authority
PL
Poland
Prior art keywords
methods
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL16715616T
Other languages
English (en)
Inventor
Jane Brown
Alan Naylor
John Paul Watts
Thomas David Mccarthy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900878A external-priority patent/AU2015900878A0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3268356T3 publication Critical patent/PL3268356T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL16715616T 2015-03-12 2016-03-09 Związki heterocykliczne i sposoby ich stosowania PL3268356T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2015900878A AU2015900878A0 (en) 2015-03-12 Heterocyclic compounds and methods for their use
AU2015902830A AU2015902830A0 (en) 2015-07-17 Heterocyclic compounds and methods for their use
PCT/IB2016/051318 WO2016142867A1 (en) 2015-03-12 2016-03-09 Heterocyclic compounds and methods for their use
EP16715616.5A EP3268356B1 (en) 2015-03-12 2016-03-09 Heterocyclic compounds and methods for their use

Publications (1)

Publication Number Publication Date
PL3268356T3 true PL3268356T3 (pl) 2022-01-24

Family

ID=60544648

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16715616T PL3268356T3 (pl) 2015-03-12 2016-03-09 Związki heterocykliczne i sposoby ich stosowania

Country Status (8)

Country Link
US (1) US10308628B2 (pl)
EP (1) EP3268356B1 (pl)
JP (1) JP6826993B2 (pl)
CN (1) CN107466293B (pl)
ES (1) ES2898635T3 (pl)
PL (1) PL3268356T3 (pl)
PT (1) PT3268356T (pl)
WO (1) WO2016142867A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001337B (zh) 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
US20240325409A1 (en) * 2023-02-27 2024-10-03 Enanta Pharmaceuticals, Inc. Fused Heterotetracyclic Antiviral Agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037890A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
ES2560327T3 (es) 2010-01-19 2016-02-18 Novartis Ag Métodos y composiciones para una velocidad de conducción nerviosa mejorada
NZ605444A (en) 2010-07-21 2015-06-26 Spinifex Pharm Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
JP6258867B2 (ja) 2012-01-25 2018-01-10 ノバルティス アーゲー 複素環式化合物およびその使用方法
EP2807171B1 (en) * 2012-01-25 2020-08-12 Novartis AG Heterocyclic compounds and methods for their use
NZ630908A (en) * 2013-07-08 2017-08-25 Novartis Ag Heterocyclic compounds and methods of their use
CN107001337B (zh) 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物

Also Published As

Publication number Publication date
EP3268356B1 (en) 2021-08-25
JP6826993B2 (ja) 2021-02-10
CN107466293A (zh) 2017-12-12
ES2898635T3 (es) 2022-03-08
EP3268356A1 (en) 2018-01-17
WO2016142867A1 (en) 2016-09-15
JP2018507897A (ja) 2018-03-22
US20180057477A1 (en) 2018-03-01
US10308628B2 (en) 2019-06-04
PT3268356T (pt) 2021-11-23
CN107466293B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
IL258180B (en) Heterocyclic compounds and their uses
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201605417QA (en) Heterocyclic compounds
PL3215147T3 (pl) Związki norketaminy osłabiającej działanie układu nerwowego i sposoby
IL252560B (en) Heterocyclic derivatives and their uses
IL247018A0 (en) Heterocyclic compound
IL246140A0 (en) History of bicyclic heterocyclics as bromodomain repressors
SG11201803213XA (en) Glycan-interacting compounds and methods of use
IL285105A (en) Heterocyclic compound
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
GB201608779D0 (en) Methods and compounds
IL251107A0 (en) Compounds and methods
EP3197885A4 (en) Heterocyclic compounds and use thereof
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
GB201608776D0 (en) Methods and compounds
PT3268356T (pt) Compostos heterocíclicos e métodos para a sua utilização
GB201416351D0 (en) Heterocyclic derivatives
AU2015903010A0 (en) Heterocyclic Compounds and Methods for their Use
AU2015902922A0 (en) Heterocyclic compounds and methods for their use
AU2015902886A0 (en) Heterocyclic Compounds And Methods For Their Use
AU2015902830A0 (en) Heterocyclic compounds and methods for their use
AU2015901751A0 (en) Heterocyclic Compounds And Methods For Their Use
AU2015900878A0 (en) Heterocyclic compounds and methods for their use
AU2015900077A0 (en) Heterocyclic compounds and methods for their use
GB201514770D0 (en) Compounds and their use